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The susceptibility of 29 Bacillus anthracis strains, collected in Hungary 
between 1933 and 2014, was tested to 10 antibiotics with commercially available 
minimum inhibitory concentration (MIC) test strips. All strains were susceptible 
to amoxicillin, ciprofloxacin, clindamycin, doxycycline, gentamicin, penicillin, ri-
fampicin, and vancomycin. Intermediate susceptibility to erythromycin and cefo-
taxime was detected in 17.2% (5/29) and 58.6% (17/29) of the strains, respec-
tively. Correlations were not observed between the isolation date, location, host 
species, genotype, and antibiotic susceptibility profile of strains.  
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Bacillus anthracis, the causative agent of anthrax, is a spore-forming, 
Gram-positive, zoonotic bacterium, a potential biological warfare agent which 
primarily infects herbivores, but can cause serious disease in humans with cuta-
neous, gastrointestinal, pulmonary, and injectional forms (WHO, 2008; Fasanella 
et al., 2010; Hanczaruk et al., 2014). The extremely resistant spore is able to sur-
vive in the soil for decades (Fasanella et al., 2010). Bacillus anthracis is suscep-
tible to most antibiotics used in therapy (Lightfoot et al., 1990; Doğanay and 
Aydin, 1991; Odendaal et al., 1991; Cavallo et al., 2002; Coker et al., 2002; Mo-
hammed et al., 2002; Turnbull et al., 2004; Luna et al., 2007; Caplan et al., 2009; 
Habrun et al., 2011; Ortatatli et al., 2012; Quinn et al., 2011). The main recom-
mended antibiotics to treat human anthrax cases are ciprofloxacin and doxycy-
cline, apart from penicillin (WHO, 2008). Animals showing clinical signs of an-
thrax are also treated with different antibiotics, mainly penicillin and oxytetracy-
cline (Quinn et al., 2011). 
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Commercially available minimum inhibitory concentration (MIC) test 
strips (Etest, BioMérieux Inc., Marcy l’Etoile, France) proved to be a simple and 
flexible method to determine the antibiotic susceptibility profiles with MIC val-
ues of B. anthracis strains. The effectiveness of the strips is comparable to that of 
conventional methods used for MIC value determination (Turnbull et al., 2004; 
Luna et al., 2007). 
The aim of this study was to determine the susceptibility of B. anthracis 
strains from Hungary to 10 antibiotics with commercially available MIC test 
strips. 
 
Materials and methods 
The study involved 29 B. anthracis strains isolated from diverse host spe-
cies in various parts of Hungary between 1933 and 2014 (Table 1). The strains 
were identified and genotyped as described previously. Briefly, the strains were 
identified on species level with a dual-probe TaqMan assay targeting a single nu-
cleotide polymorphism (SNP) in the plcR gene (Easterday et al., 2005). The 
genotypes of the isolates were determined with melt mismatch amplification mu-
tation assays according to Birdsell et al. (2012) targeting the SNPs identified by 
Van Ert et al. (2007).  
The susceptibility of the strains to 10 antimicrobial agents (amoxicillin, 
cefotaxime, ciprofloxacin, clindamycin, doxycycline, erythromycin, gentamicin, 
penicillin, rifampicin, and vancomycin) was determined with commercially 
available MIC test strips (Etest, BioMérieux Inc., Marcy l’Etoile, France). 
Staphylococcus aureus ATCC 29213T served as a positive control. The strains 
were cultured on Mueller-Hinton agar plates overnight at 37 °C. Colony suspen-
sions in 3 ml of physiological saline, equalled to a density of 0.5 McFarland, 
were consistently taken on 5 mm-thick Mueller-Hinton agar with sterile swab. 
An E-test strip was placed on each plate after approximately 10 min, to allow ab-
sorption of excess moisture into the agar. The plates were incubated at 37 °C for 
20 h and MIC values were read according to the manufacturer’s instructions. We 
interpreted the breakpoints according to Clinical and Laboratory Standards Insti-
tute (CLSI, 2011) standards for B. anthracis and CLSI standards for Staphylo-
coccus sp. where standards were unavailable for B. anthracis (Table 2). All B. 
anthracis manipulations were performed in a biosafety level 3 laboratory using 
class III biosafety cabinet. 
 
Results 
Based on the MIC90 values all Hungarian B. anthracis isolates were sus-
ceptible to penicillin (0.023 mg/L), amoxicillin (0.032 mg/L), ciprofloxacin 
(0.064 mg/L), doxycycline (0.047 mg/L), rifampicin (0.38 mg/L), vancomycin 
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(1.5 mg/L), gentamicin (0.25 mg/L), and clindamycin (0.25 mg/L) (Tables 1 and 2). 
Most of the strains (24/29, 82.8%) were susceptible to erythromycin, but interme-
diately susceptible strains (5/29, 17.2%) also occurred. The strains were suscepti-
ble (12/29, 41.4%) or intermediately (17/29, 58.6%) susceptible to cefotaxime. 
Although background information about the tested B. anthracis strains 
was limited, correlations were not observed between the isolation date, location, 
host species, genotype, and antibiotic susceptibility profile of the 29 B. anthracis 
strains (Table 1). 
Table 2 
Susceptibility profile of 29 Bacillus anthracis strains for 10 antimicrobial agents 
MIC (mg/L) Breakpoints % of isolates 
Antibiotic 
Range 50% 90% S (≤) R (≥) S I R 
Amoxicillin 0.016–0.064 0.023 0.032 0.25 0.5b 100   
Cefotaxime 0.25–16 12 16 8 64b 41.4 58.6  
Ciprofloxacin 0.023–0.064 0.047 0.064 0.5 NAa 100   
Clindamycin 0.094–0.25 0.19 0.25 0.5 4b 100   
Doxycycline 0.023–0.047 0.032 0.047 1.0 NAa 100   
Erythromycin 0.125–0.75 0.5 0.75 0.5 8b 82.8 17.2  
Gentamicin 0.047–0.38 0.125 0.25 4 16b 100   
Penicillin < 0.016–0.023 < 0.016 0.023 0.12 0.25a 100   
Rifampicin 0.004–0.5 0.19 0.38 1 4b 100   
Vancomycin 0.5–2 1 1.5 4 32b 100   
MIC: minimum inhibitory concentration; NA: data not available; S: susceptible; I: intermediate; R: 




The objective of this work was to study the antibiotic susceptibility profile 
of B. anthracis strains from Hungary. Eight of the ten examined antibiotics also 
appear on the list of antibiotics recommended for human anthrax treatment 
(WHO, 2008). 
Penicillin G is the primary recommended antibiotic to treat cutaneous an-
thrax cases without complications. Amoxicillin can be an alternative to penicillin 
(WHO, 2008). Penicillin and amoxicillin resistance was confirmed in several 
studies, within a range of 1–12% of the strains examined (Lightfoot et al., 1990; 
Cavallo et al., 2002; Coker et al., 2002; Mohammed et al., 2002; Turnbull et al., 
2004). All Hungarian strains, however, proved to be highly susceptible to peni-
cillin and amoxicillin. 
Erythromycin is also a possible alternative in case of penicillin allergy 
(WHO, 2008). Moderately sensitive strains appeared in several studies (Cavallo 
et al., 2002; Mohammed et al., 2002; Luna et al., 2007; Ortatatli et al., 2012), and 
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two resistant strains were described in Turkey (Ortatatli et al., 2012). In the cur-
rent study, 17.2% of the Hungarian strains were only intermediately sensitive to 
erythromycin. These data suggest that erythromycin should be avoided in anthrax 
treatment in Hungary. 
Ciprofloxacin and doxycycline are recommended in life-threatening cases 
and in case of penicillin allergy (WHO, 2008). Ciprofloxacin resistance has not 
been described yet. Resistance against doxycycline was observed in one strain 
(MIC 4 mg/L) in Turkey (Ortatatli et al., 2012). All examined strains from Hun-
gary were susceptible to both antibiotics. 
Rifampicin is recommended as complementary treatment in anthrax men-
ingoencephalitis, clindamycin and vancomycin in inhalation anthrax, and gen-
tamicin in gastrointestinal anthrax (WHO, 2008). Rifampicin, vancomycin and 
clindamycin resistance has not been reported yet. Gentamicin resistance was ob-
served in two cases (MIC = 32 mg/L) in Turkey (Ortatatli et al., 2012). All Hun-
garian strains proved to be susceptible to rifampicin, vancomycin, clindamycin, 
and gentamicin as well. 
Most B. anthracis stains are resistant or intermediately susceptible to cefo-
taxime according to previous findings (Doğonay and Aydin, 1991; Odendaal et 
al., 1991; Turnbull et al., 2004; Habrun et al., 2011; Ortatatli et al., 2012). 
Turnbull et al. (2004) found one susceptible strain (MIC 3 mg/L) with the Etest 
method, while Doğanay and Aydin (1991) described five susceptible strains with 
the disc diffusion test. In the present study, 41.4% of the Hungarian strains were 
susceptible to cefotaxime. Additionally, no resistant strains were identified. The 
MIC90 values proved to be lower in our study compared to other studies (Doğa-
nay and Aydin, 1991; Odendaal et al., 1991; Turnbull et al., 2004; Habrun et al., 
2011; Ortatatli et al., 2012). 
In conclusion, despite the temporal, geographic, host and genetic diversity 
of the tested B. anthracis isolates, their susceptibility profiles were highly simi-
lar. According to the present study, penicillin, amoxicillin, ciprofloxacin and 
doxycycline are the primary choices to treat anthrax, but gentamicin, vancomy-
cin, rifampicin and clindamycin could also be used against B. anthracis in Hun-
gary. The application of erythromycin and cefotaxime should be avoided in the 
treatment of anthrax. 
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